Optimising DNA-Based Cancer Vaccines for Improved Immunogenicity

Time: 4:30 pm
day: Day One


• Developing neoantigen cancer vaccines based on DNA done at a very small scale
• Addressing the reduced manufacturing time as the production process (there are a lot of benefits in quickly producing a vaccine per patient)
• Utilising the benefits of adjuvants with DNA to induce strong cancer-specific immune responses
• Currently in preclinical development and planning to move into phase 1 next year